荟萃分析:非幽门螺杆菌非NSAID消化性溃疡病的患病率
该系统评价与荟萃分析纳入92项观察性研究、60,816例患者,旨在估算非幽门螺杆菌(H. pylori)非NSAID消化性溃疡病(PUD)在总体、出血性和穿孔性PUD中的比例。结果显示总体PUD中该比例为13.0%,出血性PUD为11.3%,穿孔性PUD为22.0%;出血性PUD中该比例随研究年份更新而升高。
要点
- 非H. pylori非NSAID PUD在总体PUD中占13.0%,出血性占11.3%,穿孔性占22.0%。
- 出血性PUD中该比例随研究年份更新而升高,校正国家H. pylori患病率后仍显著。
- 国家层面H. pylori患病率越低,出血性PUD中该比例越高。
核心结论
- 非H. pylori非NSAID PUD是PUD中不可忽视但异质性较大的组成部分。
- 出血性PUD中探索性生态学分析提示该比例随时间增加,可能反映H. pylori和NSAID之外的病因模式演变。
研究设计与样本
- 系统检索MEDLINE、Embase和CENTRAL自建库至2026年3月的观察性研究。
- 共纳入92项研究、60,816例患者,来自32个国家。
- 采用限制性最大似然法对logit转换比例进行随机效应荟萃分析,并用荟萃回归评估研究年份、国家H. pylori患病率和地区的关联。
- 方案注册于PROSPERO(CRD420251174202)。
主要发现
- 非H. pylori非NSAID PUD在总体PUD中合并比例为13.0%(95%CI 10.4-16.2)。
- 在出血性PUD中为11.3%(95%CI 8.8-14.4)。
- 在穿孔性PUD中为22.0%(95%CI 13.1%-34.7%)。
- 单变量荟萃回归中,研究年份更新与出血性PUD中该比例更高相关(β=0.076;95%CI 0.031-0.120)。
- 校正国家H. pylori患病率后该关联仍显著(β=0.070;95%CI 0.026-0.113);进一步校正地区后,较低H. pylori患病率与更高比例相关(β=-0.025;95%CI -0.046至-0.005)。
临床怎么用
- 临床遇到PUD患者时应考虑非H. pylori非NSAID病因的可能,尤其在出血性或穿孔性PUD中。
- 在H. pylori患病率较低的地区,对出血性PUD患者需警惕该亚组比例升高的趋势。
局限性
- 出血性PUD中时间趋势的生态学分析为探索性,可能受混杂因素影响。
- 纳入研究为观察性研究,异质性可能影响合并比例的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-Helicobacter pylori (H. pylori), non-nonsteroidal anti-inflammatory drug (NSAID) peptic ulcer disease (PUD) is increasingly recognized as a distinct subgroup, but its proportion across clinical presentations remains unclear. AIM: We aimed to estimate this proportion. METHODS: We searched MEDLINE, Embase and CENTRAL from their inception to March 2026 for observational studies. The primary outcome was the proportion of non-H. pylori, non-NSAID PUD among adults with overall, bleeding and perforated PUD. Random-effects meta-analysis of logit-transformed proportions was performed using restricted maximum likelihood. Meta-regression assessed associations with study year, country-level H. pylori prevalence and region. Protocol registered in PROSPERO (CRD420251174202). RESULTS: Overall, 92 studies (60,816 patients) from 32 countries were included. The pooled proportions of non-H. pylori, non-NSAID PUD cases were 13.0% (95% confidence interval [CI], 10.4-16.2) in overall PUD, 11.3% (95% CI, 8.8-14.4) in bleeding PUD, and 22.0% (95% CI, 13.1%-34.7%) in perforated PUD. In univariable meta-regression, a more recent study year was associated with a higher proportion of bleeding PUD (β = 0.076; 95% CI, 0.031-0.120). This association remained statistically significant after adjustment for country-level H. pylori prevalence (β = 0.070; 95% CI, 0.026-0.113). Lower H. pylori prevalence was also associated with a higher proportion after further adjustment for region (β = -0.025; 95% CI, -0.046 to -0.005). CONCLUSION: Non-H. pylori, non-NSAID PUD represents a non-negligible but heterogeneous component of PUD. In bleeding PUD, exploratory ecological analyses suggest a temporal increase, potentially reflecting evolving etiologic patterns beyond H. pylori infection and NSAID exposure.
引用
- Watanabe J, Sekiguchi H, Kanno T, et al. Meta-Analysis: Prevalence of Non-Helicobacter pylori, Non-NSAID Peptic Ulcer Disease. Aliment Pharmacol Ther. 2026. PMID: 42572812. doi:10.1111/apt.70906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。